Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
Sponsor: Shanghai Mabgeek Biotech.Co.Ltd
Summary
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
Official title: A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of a Humanized MG-K10 Mab Injection in Subjects With Prurigo Nodularis.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2025-02-26
Completion Date
2026-11
Last Updated
2025-04-18
Healthy Volunteers
No
Conditions
Interventions
Placebo
Every four weeks, subcutaneous injection,Switch to MG-K10 treatment after 24 weeks of administration
Locations (1)
Peking University People's Hospital, Beijing,
Beijing, Bejing, China